Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M with Nivolumab and Ipilimumab in Advanced Melanoma or Renal Cell Carcinoma
NCT04495257Phase 1Completed
- Sponsor
- Yale University
- Start
- Sep 2020
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotigalimab in melanoma and renal cell carcinoma (RCC) (2 arms), sponsored by Yale University. Primary endpoints: Dose-limiting toxicities up to 2 years and Recommended dose of APX005M up to 2 years. Started Sep 2020; status: completed.
02
Drugs
sotigalimab
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04495257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495257.